On October 21, 2022, the IAEA Collaboration Center on Production and application of medical radioisotopes, radiopharmaceuticals, industrial radiotracers and sealed sources officially landed in China Tongfu. This is the fourth collaboration center in the field of drug release established by the International Atomic Energy Agency (IAEA) after France, Russia and Portugal, and the first in Asia.

　　China Atomic Energy Authority (CAEA), on behalf of the International Atomic Energy Agency (IAEA), awarded the award to China Tongfu, and the award ceremony was successfully held in Conference Room 403 of China Tongfu Building. Deng Ge, Secretary-General of China Atomic Energy Authority and his delegation, Meng Yanbin, Assistant General manager of CNNC and Zhang Guowei, Deputy general manager of China Baoyuan attended and witnessed the ceremony.

　　On behalf of the China Atomic Energy Authority, Secretary General Deng Ge affirmed the achievements made by China Tongfu in making continuous progress and deepening the nuclear technology application industry, pointing out that China Tongfu should seize the new development opportunity of the collaboration center, pursue and sail far, continue to play the role of the main force and backbone of the nuclear technology application industry, and lead the industry peers to jointly promote the high-quality development of the nuclear medical treatment and drug release industry. We will continue to improve the level of precision medicine in China, strengthen and expand our nuclear technology application industry, and help build a healthy China.

　　Meng Yanbin, Assistant general manager of CNNC, expressed his sincere gratitude to the China Atomic Energy Authority for its care and support, and stressed that the China Atomic Energy Authority has carried out a lot of systematic and pioneering work in top-level system construction, industrial planning and industry promotion. It has promoted the establishment of a series of national research and development platforms such as the Nuclear Technology (Radiopharmaceutical Engineering Transformation) Research Center of the China Atomic Energy Authority, and built a high-level and high-quality cooperation and exchange platform for the development of enterprises. The nuclear technology application industry has ushered in the best development period. The nuclear technology application enterprises of CNNC Group should make good use of policies and integrate internal resources. Under the leadership of the China Atomic Energy Authority, we will continue to strengthen the development of the nuclear technology application industry, lead development with innovation, and empower a better life with nuclear technology.